Acute and chronic respiratory diseases (rhinosinusitis, otitis and pharyngitis) and dermatological complaints (herpes zoster, herpes simplex eczema, fungi and acne) have been the focus of our research up until now.

We already market Nasodren® (whose active ingredient is an extract of Cyclamen europaeum L.), a radically new treatment to combat rhinosinusitis and other respiratory diseases, with more than 2 million units sold worldwide. Thanks to its innovative mechanism of action, it is an effective and safe alternative to antibiotics, providing symptom relief and a cure for those affected, without the need for surgical intervention or multiple treatments (more than 3-4 treatments are associated with habitual clinical practice).

Clinical trials in the area of dermatology have been carried out after years of studies with Lazolex®.

New studies with Nasodren® widen its range of possible indications for treating important respiratory diseases and other highly prevalent pathologies.

The introduction of Hartington products in other medical fields, such as Oncology, Rheumatology and Orthopaedic Surgery, is also expected.

Our main challenge is RESEARCH, dedicating 25% of annual revenue to the research department for preclinical and clinical studies.

Vakhtang MtchedlidzeR&D Director